Monthly Archives: February 2013

Celgene CEO on New Multiple Myeloma Drug Approvals

BIO CEO

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

STEM Education Aimed at Girls

STEM

We write a fair bit about STEM education here at BIOtechNOW, so I was a bit surprised to come across a word I’d never heard before. STEMinists  may be a made-up word, but it’s still a good one. In case you haven’t figured it out yet, let me help you: STEM + feminists =  STEMinists. In other words, it’s a young women who’s interested in science, technology, engineering and math (STEM) fields. As the father Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

Biotech Hall of Fame: Interview with Biotech’s First Investment Banker

Biotech Hall of Fame

Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Brazil Patent Policy: At a Crossroads

Photo By: DigiDreamGrafix.com

The Government of Brazil approaches the patent policy crossroads with two ministries wanting to move in opposite directions.  In the last few months, both the Brazilian Patent Office (INPI) and the Brazilian Regulatory Authority (ANVISA) issued proposed rules concerning patents and are sifting through public comments to determine how they will deal with biotech patents. A quirk in Brazilian law requires that the health regulatory authority (ANVISA) must provide “prior consent” on the grant of a pharmaceutical patent.  Traditionally, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

A Call to Arms for Renewable Fuels

Jim Greenwood

BIO President & CEO Jim Greenwood delivered remarks on the Renewable Fuel Standard and participated in a panel session on the Legacy of Bipartisan Support for Renewable Energy at ACORE’s National Renewable Energy Policy Forum, held on Capitol Hill: Good afternoon. It is good to be with ACORE again and to be part of your 10th annual policy forum. I had the pleasure of speaking at the RETECH 2012 conference in October. I said then Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,